Gain Therapeutics, Inc. (GANX) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Gain Therapeutics, Inc. (GANX) Bundle
Explore Gain Therapeutics, Inc. (GANX) financial outlook with our user-friendly DCF Calculator! Simply enter your assumptions for growth, margins, and expenses to calculate the intrinsic value of Gain Therapeutics, Inc. (GANX) and inform your investment decisions.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .2 | .1 | .1 | .1 | .1 | .1 | .1 | .1 |
| Revenue Growth, % | 0 | -30.07 | 471.29 | -15.08 | -60.62 | -1.44 | -1.44 | -1.44 | -1.44 | -1.44 |
| EBITDA | -2.1 | -3.5 | -13.8 | -17.8 | -22.2 | -.1 | -.1 | -.1 | -.1 | -.1 |
| EBITDA, % | -5078.66 | -12014.32 | -8377.29 | -12688.1 | -40176.79 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .0 | .0 | .0 | .1 | .1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 6.23 | 33.21 | 9.38 | 45.8 | 151.47 | 38.92 | 38.92 | 38.92 | 38.92 | 38.92 |
| EBIT | -2.1 | -3.5 | -13.8 | -17.8 | -22.3 | -.1 | -.1 | -.1 | -.1 | -.1 |
| EBIT, % | -5084.89 | -12047.54 | -8386.67 | -12733.9 | -40328.26 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | .3 | 7.5 | 36.9 | 20.1 | 16.8 | .1 | .1 | .1 | .1 | .1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .1 | .1 | .1 | .2 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 108.75 | 230.48 | 68.84 | 74.14 | 439.61 | 88.6 | 88.6 | 88.6 | 88.6 | 88.6 |
| Inventories | .0 | 1.4 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 76.22 | 4699.86 | 0 | 0 | 0 | 35.24 | 35.24 | 35.24 | 35.24 | 35.24 |
| Accounts Payable | .2 | 1.0 | .6 | 1.6 | 1.3 | .1 | .1 | .1 | .1 | .1 |
| Accounts Payable, % | 373.94 | 3329.23 | 339.7 | 1160.6 | 2390.3 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | -.1 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -33.23 | -72.11 | -57.1 | -84.9 | -27.83 | -55.03 | -55.03 | -55.03 | -55.03 | -55.03 |
| Tax Rate, % | -0.35728 | -0.35728 | -0.35728 | -0.35728 | -0.35728 | -0.35728 | -0.35728 | -0.35728 | -0.35728 | -0.35728 |
| EBITAT | -2.1 | -3.5 | -13.8 | -17.9 | -22.3 | -.1 | -.1 | -.1 | -.1 | -.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2.0 | -4.0 | -13.0 | -16.9 | -22.7 | -1.2 | -.1 | -.1 | -.1 | -.1 |
| WACC, % | 5.97 | 5.97 | 5.97 | 5.97 | 5.97 | 5.97 | 5.97 | 5.97 | 5.97 | 5.97 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -2 | |||||||||
| Present Terminal Value | -1 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -11 | |||||||||
| Equity Value | 8 | |||||||||
| Diluted Shares Outstanding, MM | 13 | |||||||||
| Equity Value Per Share | 0.64 |
What You Will Get
- Comprehensive GANX Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Intrinsic value and NPV are updated automatically.
- Scenario Analysis: Evaluate various scenarios to assess Gain Therapeutics’ future performance.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Pre-Loaded Data: Gain Therapeutics’ historical financial statements and pre-filled forecasts.
- Fully Adjustable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Instant Results: View Gain Therapeutics’ intrinsic value recalculated in real time.
- Clear Visual Outputs: Dashboard charts present valuation results and essential metrics.
- Built for Accuracy: A professional tool designed for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Gain Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Gain Therapeutics’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Gain Therapeutics, Inc. (GANX)?
- Accuracy: Utilizes real Gain Therapeutics financial data for precise calculations.
- Flexibility: Tailored for users to easily adjust and experiment with various inputs.
- Time-Saving: Avoid the complexity of creating a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and attention to detail expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Investors: Evaluate Gain Therapeutics, Inc. (GANX) to inform stock trading decisions.
- CFOs and Financial Analysts: Enhance valuation workflows and assess financial forecasts for GANX.
- Startup Founders: Understand the valuation strategies of biotech companies like Gain Therapeutics, Inc. (GANX).
- Consultants: Provide comprehensive valuation analyses and reports for clients interested in GANX.
- Students and Educators: Utilize current data to practice and teach valuation methodologies relevant to GANX.
What the Template Contains
- Preloaded GANX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.